- Home
- CABA vs REKR Comparison
CABA vs REKR Comparison
Compare CABA & REKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- REKR
- Stock Information
- Founded
- CABA 2017
- REKR 2017
- Country
- CABA United States
- REKR United States
- Employees
- CABA N/A
- REKR N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- REKR Telecommunications Equipment
- Sector
- CABA Health Care
- REKR Telecommunications
- Exchange
- CABA Nasdaq
- REKR Nasdaq
- Market Cap
- CABA 157.4M
- REKR 153.5M
- IPO Year
- CABA 2019
- REKR N/A
- Fundamental
- Price
- CABA $1.60
- REKR $1.16
- Analyst Decision
- CABA Strong Buy
- REKR
- Analyst Count
- CABA 8
- REKR 0
- Target Price
- CABA $18.88
- REKR N/A
- AVG Volume (30 Days)
- CABA 3.0M
- REKR 7.0M
- Earning Date
- CABA 08-07-2025
- REKR 08-13-2025
- Dividend Yield
- CABA N/A
- REKR N/A
- EPS Growth
- CABA N/A
- REKR N/A
- EPS
- CABA N/A
- REKR N/A
- Revenue
- CABA N/A
- REKR $45,448,000.00
- Revenue This Year
- CABA N/A
- REKR $8.68
- Revenue Next Year
- CABA N/A
- REKR $21.45
- P/E Ratio
- CABA N/A
- REKR N/A
- Revenue Growth
- CABA N/A
- REKR 17.97
- 52 Week Low
- CABA $0.99
- REKR $0.62
- 52 Week High
- CABA $8.77
- REKR $2.67
- Technical
- Relative Strength Index (RSI)
- CABA 42.81
- REKR 47.43
- Support Level
- CABA $1.65
- REKR $1.08
- Resistance Level
- CABA $1.83
- REKR $1.50
- Average True Range (ATR)
- CABA 0.14
- REKR 0.09
- MACD
- CABA -0.06
- REKR -0.02
- Stochastic Oscillator
- CABA 17.86
- REKR 19.05
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.